Peer-reviewed veterinary case report
Spatial metabolomics reveals the therapeutic mechanisms of Shengjiang Xiexin decoction in modulating gut-liver axis fatty acid metabolism for the treatment of Clostridioides difficile infection.
- Journal:
- Journal of ethnopharmacology
- Year:
- 2026
- Authors:
- Xu, Yue et al.
- Affiliation:
- Department of Pharmacy · China
- Species:
- rodent
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE: Shengjiang Xiexin Decoction (SXD) is a classic formula documented in the Treatise on Cold Damage and Miscellaneous Diseases. It has long been used to treat infectious gastrointestinal diseases characterized by diarrhea, dysentery, and abdominal distension. Its core pathogenesis involves spleen-stomach disharmony and damp-heat accumulation, consistent with clinical features of bacterial or viral enteritis. Although SXD effectively relieves gastrointestinal symptoms, its active components and mechanisms remain unclear, especially regarding spatial regulation of gut-liver axis metabolism. AIM OF THE STUDY: We aim to map the spatial landscape of gut-liver axis metabolism regulated by SXD in CDI-induced mice, by employing a strategy that combines whole-animal mass spectrometry imaging (MSI) technology with spatial metabolomics. METHODS: After CDI modeling and SXD intervention, intestinal injury was evaluated by biochemical and histopathological analysis. MSI was used for in situ detection of SXD active components, and spatial metabolomics to investigate its regulatory effects on gut-liver axis metabolic disorders. RESULTS: SXD attenuated colonic mucosal epithelial detachment and suppressed inflammation. MSI identified wogonin, glycyrrhizic acid, shogaol, gingerenone B, feruloyltyramine, and paradol as key active components targeting the gut-liver axis. Spatial metabolomics demonstrated that SXD reduced intestinal accumulation of medium- and long-chain fatty acids (MCFAs and LCFAs), alleviated hepatic metabolic imbalance characterized by excessive short-chain FA accumulation and MCFA/LCFA depletion, and restored FA homeostasis across the disrupted gut-liver axis. CONCLUSION: SXD ameliorates CDI-induced gut-liver injury through multiple pathways, including regulating gut-liver axis inflammatory responses, and FA metabolism.​ From a spatial perspective, this study achieved in situ characterization of SXD's mode of action, providing valuable information for investigating its material basis and mechanisms.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://pubmed.ncbi.nlm.nih.gov/41839301/